Oragenics, Inc. (OGEN)
NYSEAMERICAN: OGEN · Real-Time Price · USD
3.530
-0.170 (-4.59%)
Jun 5, 2025, 4:00 PM - Market closed
Oragenics Employees
Oragenics had 5 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,066,816
Market Cap
2.53M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
OGEN News
- 23 days ago - Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - GlobeNewsWire
- 24 days ago - Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress - GlobeNewsWire
- 2 months ago - Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K - GlobeNewsWire
- 3 months ago - Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI) - GlobeNewsWire
- 3 months ago - Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment - GlobeNewsWire
- 4 months ago - Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment - GlobeNewsWire